First Capital Advisors Group’s Tvardi Therapeutics TVRD Stock Holding History

First Capital Advisors Group’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$495	Buy	+5	New	+$689	﹤0.01%	918

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Capital Advisors Group's TVRD Position: Q2 2023 in Review

First Capital Advisors Group opened a new position in Tvardi Therapeutics (TVRD) in Q2 2023: 5 shares worth $495. The stake represents ﹤0.01% of the portfolio and ranks #918 among its holdings.

136 funds tracked by Wall St. Rank hold TVRD as of Q2 2023.

First Capital Advisors Group held 5 shares of Tvardi Therapeutics worth $495 as of Q2 2023.
Tvardi Therapeutics was a new First Capital Advisors Group position in Q2 2023.
Tvardi Therapeutics made up ﹤0.01% of First Capital Advisors Group's portfolio in Q2 2023, its #918 holding.
136 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2023.

Based on First Capital Advisors Group's 13F filing for Q2 2023, filed 15 Aug 2023.